Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa H Butterfield

Showing results (81-90 of 176) with videos related to

Pageof 18
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 17, 2009
Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitroMichael W Lipscomb, Lu Chen, Jennifer L Taylor, et al.
Journal for Immunotherapy of Cancer|April 21, 2016
Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancerMichal Radomski, Herbert J Zeh, Howard D Edington, et al.
Nature Communications|September 2, 2022
Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cellsJuraj Adamik, Paul V Munson, Felix J Hartmann, et al.
Journal of Translational Medicine|May 23, 2022
The future of cancer immunotherapy for brain tumors: a collaborative workshopChristine E Brown, Samantha Bucktrout, Lisa H Butterfield, et al.
Cancer Immunology Research|May 5, 2017
Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell DeathLazar Vujanovic, Elizabeth C Stahl, Angela D Pardee, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Cancer Gene Therapy|March 19, 2005
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cellsJennifer A Wargo, Lana Y Schumacher, Begonya Comin-Anduix, et al.
JAMA|November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialF Stephen Hodi, Sandra Lee, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Craig L Slingluff, Sandra Lee, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I dendritic cell p53 peptide vaccine for head and neck cancerPatrick J Schuler, Malgorzata Harasymczuk, Carmen Visus, et al.
Pageof 18

Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
Journal of Immunology (Baltimore, Md. : 1950)|November 17, 2009
Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitroMichael W Lipscomb, Lu Chen, Jennifer L Taylor, et al.
Journal for Immunotherapy of Cancer|April 21, 2016
Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancerMichal Radomski, Herbert J Zeh, Howard D Edington, et al.
Nature Communications|September 2, 2022
Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cellsJuraj Adamik, Paul V Munson, Felix J Hartmann, et al.
Journal of Translational Medicine|May 23, 2022
The future of cancer immunotherapy for brain tumors: a collaborative workshopChristine E Brown, Samantha Bucktrout, Lisa H Butterfield, et al.
Cancer Immunology Research|May 5, 2017
Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell DeathLazar Vujanovic, Elizabeth C Stahl, Angela D Pardee, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Cancer Gene Therapy|March 19, 2005
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cellsJennifer A Wargo, Lana Y Schumacher, Begonya Comin-Anduix, et al.
JAMA|November 5, 2014
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialF Stephen Hodi, Sandra Lee, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Craig L Slingluff, Sandra Lee, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I dendritic cell p53 peptide vaccine for head and neck cancerPatrick J Schuler, Malgorzata Harasymczuk, Carmen Visus, et al.
Pageof 18